http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 17:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html <p align="justify">BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq http://www.streetinsider.com/Press+Releases/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html Mon, 01 Jun 2026 17:00:00 -0400 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html <p align="justify">BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq http://www.streetinsider.com/Press+Releases/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html Mon, 01 Jun 2026 17:00:00 -0400 O.48279457 VOR http://www.streetinsider.com/Globe+Newswire/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html <p align="justify">BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq http://www.streetinsider.com/Globe+Newswire/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html Mon, 01 Jun 2026 17:00:00 -0400 O.48279457 VOR http://www.streetinsider.com/Globe+Newswire/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html <p align="justify">BOSTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on June 1, 2026, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 61,050 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 12,900 shares of Vor Bio’s common stock to 10 newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq http://www.streetinsider.com/Globe+Newswire/Vor+Bio+Reports+Inducement+Grant+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26584816.html Mon, 01 Jun 2026 17:00:00 -0400 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html <p align="justify">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.</p> <p align="justify">Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET</p> <p align="justify">A live webcast of the presentation may be accessed on the Investors section of the Vor website at <a target="_blank" href="http://ir.vorbio.com">ir.vorbio.com</a>. A replay of the webcast will be available on the Vor website for approximately 30 days following http://www.streetinsider.com/Press+Releases/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html Thu, 28 May 2026 08:30:00 -0400 O.48279457 VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html <p align="justify">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.</p> <p align="justify">Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET</p> <p align="justify">A live webcast of the presentation may be accessed on the Investors section of the Vor website at <a target="_blank" href="http://ir.vorbio.com">ir.vorbio.com</a>. A replay of the webcast will be available on the Vor website for approximately 30 days following http://www.streetinsider.com/Press+Releases/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html Thu, 28 May 2026 08:30:00 -0400 O.48279457 VOR http://www.streetinsider.com/Globe+Newswire/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html <p align="justify">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.</p> <p align="justify">Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET</p> <p align="justify">A live webcast of the presentation may be accessed on the Investors section of the Vor website at <a target="_blank" href="http://ir.vorbio.com">ir.vorbio.com</a>. A replay of the webcast will be available on the Vor website for approximately 30 days following http://www.streetinsider.com/Globe+Newswire/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html Thu, 28 May 2026 08:30:00 -0400 O.48279457 VOR http://www.streetinsider.com/Globe+Newswire/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html <p align="justify">BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will provide a corporate update in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY.</p> <p align="justify">Presentation: Wednesday, June 3, 2026 at 9:55am – 10:25 am ET</p> <p align="justify">A live webcast of the presentation may be accessed on the Investors section of the Vor website at <a target="_blank" href="http://ir.vorbio.com">ir.vorbio.com</a>. A replay of the webcast will be available on the Vor website for approximately 30 days following http://www.streetinsider.com/Globe+Newswire/Vor+Bio+to+Participate+in+the+2026+Jefferies+Global+Healthcare+Conference/26561727.html Thu, 28 May 2026 08:30:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26506703.html si-local-file:///var/storage/secattach/20260515/26506703.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26506703.html Fri, 15 May 2026 16:37:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26506703.html si-local-file:///var/storage/secattach/20260515/26506703.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Venrock+Healthcare+Capital+Partners+III%2C+L.P./26506703.html Fri, 15 May 2026 16:37:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Verve+Capital+Ltd/26506522.html si-local-file:///var/storage/secattach/20260515/26506522.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Verve+Capital+Ltd/26506522.html Fri, 15 May 2026 16:34:00 -0400 O.48279457 VOR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Verve+Capital+Ltd/26506522.html si-local-file:///var/storage/secattach/20260515/26506522.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Vor+Biopharma+Inc.+++++++++++++++++++++Filed+by%3A+Verve+Capital+Ltd/26506522.html Fri, 15 May 2026 16:34:00 -0400 O.48279457 VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html <p>Vor Bio (NASDAQ: VOR) announced that results from a Phase 3 trial of telitacicept for IgA nephropathy were published in The New England Journal of Medicine. The trial, called TELIGAN, was conducted in China by collaborator RemeGen Co., Ltd. (HKEX: 9995, SHA: 688331).</p> <p>The interim analysis showed telitacicept reduced proteinuria by 55.0% relative to placebo at 39 weeks. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio, compared with an 8.8% reduction for placebo.</p> <p>The study met its primary endpoint with statistical significance. Estimated glomerular filtration rate remained stable with telitacicept, showing a mean percentage change http://www.streetinsider.com/FDA/Vor+Bio+reports+positive+telitacicept+trial+results+in+kidney+disease/26490625.html Thu, 14 May 2026 08:30:30 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html <p align="center"><em>Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment </em></p> <p align="center"><em>Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases</em></p> <p align="justify">BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in <em>The New England Journal of http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html Thu, 14 May 2026 08:30:00 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html <p align="center"><em>Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment </em></p> <p align="center"><em>Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases</em></p> <p align="justify">BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in <em>The New England Journal of http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html Thu, 14 May 2026 08:30:00 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html <p align="center"><em>Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment </em></p> <p align="center"><em>Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases</em></p> <p align="justify">BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in <em>The New England Journal of http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html Thu, 14 May 2026 08:30:00 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html <p align="center"><em>Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment </em></p> <p align="center"><em>Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases</em></p> <p align="justify">BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in <em>The New England Journal of http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html Thu, 14 May 2026 08:30:00 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html <p align="center"><em>Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment </em></p> <p align="center"><em>Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases</em></p> <p align="justify">BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in <em>The New England Journal of http://www.streetinsider.com/Press+Releases/Vor+Bio+Announces+Publication+of+Interim+Analysis+of+TELIGAN%2C+a+China+Phase+3+Trial+of+Telitacicept+in+IgA+Nephropathy%2C+in+The+New+England+Journal+of+Medicine/26490599.html Thu, 14 May 2026 08:30:00 -0400 688331 9995 A.09649487 O.00048429 O.33620320 O.48279457 REGMY VOR